154 related articles for article (PubMed ID: 30617155)
1. Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.
Zhang X; Nguyen KD; Rudnick PA; Roper N; Kawaler E; Maity TK; Awasthi S; Gao S; Biswas R; Venugopalan A; Cultraro CM; Fenyö D; Guha U
Mol Cell Proteomics; 2019 Apr; 18(4):622-641. PubMed ID: 30617155
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.
Biswas R; Gao S; Cultraro CM; Maity TK; Venugopalan A; Abdullaev Z; Shaytan AK; Carter CA; Thomas A; Rajan A; Song Y; Pitts S; Chen K; Bass S; Boland J; Hanada KI; Chen J; Meltzer PS; Panchenko AR; Yang JC; Pack S; Giaccone G; Schrump DS; Khan J; Guha U
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001263. PubMed ID: 27900369
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
4. CDK12 loss inhibits cell proliferation by regulating TBK1 in non-small cell lung cancer cells.
Liu X; Liu Y; Chai W; Yan M; Li H; Li J; Sun L; Cao Y; Liu Q; Sun Y; Pan H
Mol Cell Probes; 2023 Oct; 71():101923. PubMed ID: 37517598
[TBL] [Abstract][Full Text] [Related]
5. Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma.
Ito M; Miyata Y; Hirano S; Kimura S; Irisuna F; Ikeda K; Kushitani K; Kishi N; Tsutani Y; Takeshima Y; Okada M
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2325-2333. PubMed ID: 31317326
[TBL] [Abstract][Full Text] [Related]
6. Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8
Ji J; Zhou C; Wu J; Cai Q; Shi M; Zhang H; Yu Y; Zhu Z; Zhang J
Int J Med Sci; 2019; 16(8):1142-1148. PubMed ID: 31523177
[No Abstract] [Full Text] [Related]
7. Proteogenomics connects somatic mutations to signalling in breast cancer.
Mertins P; Mani DR; Ruggles KV; Gillette MA; Clauser KR; Wang P; Wang X; Qiao JW; Cao S; Petralia F; Kawaler E; Mundt F; Krug K; Tu Z; Lei JT; Gatza ML; Wilkerson M; Perou CM; Yellapantula V; Huang KL; Lin C; McLellan MD; Yan P; Davies SR; Townsend RR; Skates SJ; Wang J; Zhang B; Kinsinger CR; Mesri M; Rodriguez H; Ding L; Paulovich AG; Fenyö D; Ellis MJ; Carr SA;
Nature; 2016 Jun; 534(7605):55-62. PubMed ID: 27251275
[TBL] [Abstract][Full Text] [Related]
8. Integrative Proteomic Characterization of Human Lung Adenocarcinoma.
Xu JY; Zhang C; Wang X; Zhai L; Ma Y; Mao Y; Qian K; Sun C; Liu Z; Jiang S; Wang M; Feng L; Zhao L; Liu P; Wang B; Zhao X; Xie H; Yang X; Zhao L; Chang Y; Jia J; Wang X; Zhang Y; Wang Y; Yang Y; Wu Z; Yang L; Liu B; Zhao T; Ren S; Sun A; Zhao Y; Ying W; Wang F; Wang G; Zhang Y; Cheng S; Qin J; Qian X; Wang Y; Li J; He F; Xiao T; Tan M
Cell; 2020 Jul; 182(1):245-261.e17. PubMed ID: 32649877
[TBL] [Abstract][Full Text] [Related]
9. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
[TBL] [Abstract][Full Text] [Related]
10. EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del/L858R mutations.
Xia L; Wang H; Xiao H; Lan B; Liu J; Yang Z
Thorac Cancer; 2020 Oct; 11(10):2755-2766. PubMed ID: 32881299
[TBL] [Abstract][Full Text] [Related]
11. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Shan W; Yuan J; Hu Z; Jiang J; Wang Y; Loo N; Fan L; Tang Z; Zhang T; Xu M; Pan Y; Lu J; Long M; Tanyi JL; Montone KT; Fan Y; Hu X; Zhang Y; Zhang L
Cell Rep; 2020 Jul; 32(2):107884. PubMed ID: 32668240
[TBL] [Abstract][Full Text] [Related]
12. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
13. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
Schweppe DK; Rigas JR; Gerber SA
J Proteomics; 2013 Oct; 91():286-96. PubMed ID: 23911959
[TBL] [Abstract][Full Text] [Related]
14. Tumor Immune Microenvironment Characterization of Primary Lung Adenocarcinoma and Lymph Node Metastases.
Zhou Y; Shi X; Chen H; Mao B; Song X; Gao L; Zhang J; Yang Y; Zhang H; Wang G; Zhuang W
Biomed Res Int; 2021; 2021():5557649. PubMed ID: 34337026
[TBL] [Abstract][Full Text] [Related]
15.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Zhang X; Maity T; Kashyap MK; Bansal M; Venugopalan A; Singh S; Awasthi S; Marimuthu A; Charles Jacob HK; Belkina N; Pitts S; Cultraro CM; Gao S; Kirkali G; Biswas R; Chaerkady R; Califano A; Pandey A; Guha U
Mol Cell Proteomics; 2017 May; 16(5):891-910. PubMed ID: 28331001
[TBL] [Abstract][Full Text] [Related]
17. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.
Lin P; Yao Z; Sun Y; Li W; Liu Y; Liang K; Liu Y; Qin J; Hou X; Chen L
J Proteomics; 2019 Jul; 204():103414. PubMed ID: 31195151
[TBL] [Abstract][Full Text] [Related]
18. p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.
Gu MM; Gao D; Yao PA; Yu L; Yang XD; Xing CG; Zhou J; Shang ZF; Li M
Cancer Sci; 2018 Dec; 109(12):3783-3793. PubMed ID: 30281878
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
20. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]